Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Tivozanib (AV-951): Potent and Selective VEGFR Inhibitor ...

    2026-03-12

    Tivozanib (AV-951): Potent and Selective VEGFR Inhibitor for Cancer Therapy

    Executive Summary: Tivozanib (AV-951) achieves sub-nanomolar (160 pM) inhibition of VEGFR-2, outperforming first-generation TKIs in selectivity and potency (Schwartz 2022). In preclinical xenograft models of renal cell carcinoma (RCC), it demonstrates significant anti-tumor efficacy and minimal off-target kinase inhibition. Clinically, Tivozanib extends median progression-free survival (PFS) to 12.7 months in metastatic RCC patients. Combination regimens with EGFR inhibitors yield synergistic anti-proliferative effects in ovarian carcinoma lines. APExBIO provides Tivozanib (SKU: A2251) with validated purity and solubility for experimental reproducibility.

    Biological Rationale

    Angiogenesis is essential for tumor growth and metastasis. The vascular endothelial growth factor receptor (VEGFR) family—VEGFR-1, VEGFR-2, and VEGFR-3—mediates endothelial cell proliferation, survival, and vascular permeability. VEGFR-2 is the primary transducer of VEGF-A-driven angiogenic signaling (Schwartz 2022). Inhibition of the VEGFR pathway reduces neovascularization and restricts tumor progression. Selective disruption of VEGFR signaling, with minimal off-target kinase inhibition, is a core principle in anti-angiogenic therapy for solid tumors, especially renal cell carcinoma (RCC), hepatocellular carcinoma, and certain ovarian cancers.

    Mechanism of Action of Tivozanib (AV-951)

    Tivozanib is a quinoline-urea derivative designed as a second-generation tyrosine kinase inhibitor (TKI). It binds the ATP-binding pocket of VEGFR-1, VEGFR-2, and VEGFR-3, blocking receptor autophosphorylation and subsequent downstream signaling. Tivozanib exhibits an IC50 of 160 pM for VEGFR-2, 21 nM for VEGFR-1, and 15 nM for VEGFR-3 in biochemical assays. In cell-based assays, it inhibits VEGFR-2 phosphorylation at concentrations as low as 1 nM. Tivozanib displays low inhibition of off-target kinases including c-KIT (IC50 > 1 μM) and PDGFRβ (IC50 ~ 100 nM), resulting in minimal hematopoietic toxicity (Schwartz 2022). The compound is orally bioavailable and demonstrates favorable pharmacokinetics in preclinical models.

    Evidence & Benchmarks

    • Tivozanib inhibits VEGFR-2 kinase activity with an IC50 of 160 pM in enzymatic assays (DOI:10.13028/wced-4a32).
    • In RCC xenograft models, Tivozanib reduces tumor volume by >70% after 21 days of oral administration (1.5 mg/kg/day) (DOI:10.13028/wced-4a32).
    • Phase III clinical trial: Tivozanib yields a median progression-free survival (PFS) of 12.7 months in metastatic RCC, compared to 9.1 months for sorafenib (DOI:10.13028/wced-4a32).
    • Combination with EGFR inhibitors (e.g., erlotinib) enhances apoptosis and growth inhibition in ovarian carcinoma cell lines (10 μM, 48 hr) (DOI:10.13028/wced-4a32).
    • Tivozanib demonstrates superior selectivity index over sunitinib, pazopanib, and sorafenib in kinase panels (DOI:10.13028/wced-4a32).

    This article extends the analysis in Tivozanib (AV-951): Potent and Selective VEGFR Inhibitor ... by providing detailed quantitative benchmarks and updated clinical data.

    For a comparative perspective on pan-VEGFR inhibition and experimental troubleshooting, see Tivozanib: Potent VEGFR Inhibitor for Precision Oncology .... This current article emphasizes combination strategies and workflow integration.

    Further details on experimental protocols and reproducibility can be found in Tivozanib (AV-951): Potent and Selective VEGFR Inhibitor ..., whereas this review provides updated clinical outcomes and practical storage/solubility recommendations.

    Applications, Limits & Misconceptions

    Tivozanib is used for:

    • Preclinical anti-angiogenic studies in RCC and other solid tumor models.
    • Clinical treatment of metastatic RCC at 1.5 mg orally, once daily, for 3 weeks on/1 week off cycles.
    • In vitro combination therapy assays with EGFR or PDGFR inhibitors.
    • VEGFR signaling pathway inhibition studies in endothelial and carcinoma cell lines.

    Common Pitfalls or Misconceptions

    • Not effective in VEGFR-independent tumors: Tivozanib does not inhibit tumor growth in models lacking VEGFR expression.
    • Not a broad-spectrum kinase inhibitor: Minimal activity against kinases such as c-KIT, B-RAF, or SRC limits its use to VEGFR-driven pathologies.
    • Water insolubility: Tivozanib is insoluble in water; DMSO or ethanol (with gentle warming) are required for stock solutions.
    • Long-term solution instability: Stock solutions should not be stored for extended periods; fresh preparation is recommended.
    • Not validated for non-cancer or non-angiogenic diseases: Limited evidence supports use outside oncology research.

    Workflow Integration & Parameters

    APExBIO supplies Tivozanib (AV-951, SKU: A2251) as a solid with a molecular weight of 454.86 g/mol and formula C22H19ClN4O5 (product page). It is soluble at ≥22.75 mg/mL in DMSO and ≥2.68 mg/mL in ethanol, but insoluble in aqueous buffers. Recommended storage is at -20°C, protected from light and moisture. For in vitro cell assays, use at 10 μM for 48 hours. In vivo dosing (preclinical) is typically 1.5 mg/kg/day orally. Tivozanib solutions should be prepared fresh and not stored long-term. APExBIO provides validated batch documentation for reproducibility.

    Conclusion & Outlook

    Tivozanib (AV-951) is a robust, highly selective pan-VEGFR inhibitor that sets a benchmark for anti-angiogenic therapy research. Its potency, selectivity, and clinical efficacy in RCC make it a preferred tool for translational oncology. Current trends focus on rational combination therapy (e.g., with EGFR inhibitors) and precision medicine applications. Future studies will address resistance mechanisms and expand use in other VEGF-driven malignancies. For detailed product information and technical support, consult the APExBIO Tivozanib (AV-951) product page.